Loyalty is not loyalty unless one clings to it in the face of adversity.” ― Lisa Tawn Bergren
It has been quite a while since we looked at Aerie Pharmaceuticals (AERI). The stock, like most small biotech stocks, was crushed in the back half of 2018. However, the shares have acquitted themselves well so far in 2019. I have gotten a few questions from around this name recently. With a key PDUFA date in mid-March, it is time to revisit this ocular concern.
Aerie Pharmaceuticals is a North Carolina based ophthalmic pharmaceutical company, focuses on the development and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases. The stock came public late in 2013 and sports a market capitalization just north of $2 billion. It stock currently trades for just over $45 a share after a nice rally in January.
Product Portfolio & Pipeline:
Rhopressa was approved to treat glaucoma late in 2017 and rolled out in the first half of 2018. Rhopressa is a once daily treatment that lowers eye pressure in patients with open-angle glaucoma and ocular hypertension. In the third quarter, the compound did $7.2 million in revenues. The company expects Rhopressa will generate between $20 million to $30 million in sales in FY2018.
Aerie’s next potential approval is for Roclatan which has a March 14th PDUFA date. Roclatan is a once-daily eye drop that combines netarsudil—the active ingredient in our approved product, Rhopressa® 0.02%—with latanoprost, prostaglandin analog (PGA) that is the most commonly-prescribed medication for lowering Inter Ocular Pressure (IOP) to treat glaucoma.
In recent news, ten days ago the FDA accepted Aerie's IND application for AR-1105 (dexamethasone intravitreal implant) for the treatment of macular edema due to retinal vein occlusion. A Phase 2 clinical study is expected to begin later this quarter.
To pick up a free report entitled '10 Simple Rules To Trade Options Like A Pro' which is for those that want to learn more about profitably using options strategies and add that to their investing 'toolbox'. It is now available free via download HERE
Analyst Commentary & Balance Sheet:
The current median analyst price target on Aerie is just north of $80 a share. So far in 2019, both Cantor Fitzgerald ($86 price target) and Mizuho Securities ($77 price target) have reissued Buy ratings on the stock. Here is the commentary from Cantor's call which came out on January 9th
We rate Aerie Pharmaceuticals Overweight. AERI is commercializing and developing once-daily eye drops, respectively, for glaucoma. Rhopressa is the first novel drug in a market that has not seen innovation in 20 years. Valuation Summary We value Aerie based on the NPV of the cash flows associated with its glaucoma drug candidates. Our target price is $86/share.”
The company came out of the third quarter with just over $235 million of cash on hand. Management guided that it expected cash burn for FY2018 to be in the $210 million to $215 million range after burning through $163 million in the first nine months of 2018.
Aerie looks poised to add a second compound to its product portfolio in Mid-March and continues to advance its pipeline. The stock also enjoys solid analyst support and could continue to run up a bit into its March PDUFA date.
That said, we have seen sell-offs after FDA approvals in the biotech space overall including in fellow ocular concern Ocular Therapeutix (OCUL) whose product DEXTENZA received FDA approval on December 3rd of last year. In addition, it appears the company is going to have to raise additional funding sometime this year. Finally, insiders were frequent sellers of the shares throughout 2018.
I have a small 'watch item' holding in AERI. I have no plans to add to my holdings currently and if I was going to take an initial position in AERI, it would be through a buy-write option order. Post approval/capital raise, I may revisit this name to see if the risk/reward profile has improved. I offer this analysis up for the several folks that have inquired on this name recently.
The most reliable friend you have is your shadow.” ― Matshona Dhliwayo
Those signed up to receive the free reports we put out once or twice a month received our in-depth look at an 'off the radar' nine percent yield play yesterday. Those not signed up, just click here and download this granular investment analysis from the 'free reports' page on this unique high yield concern I recently added to my own income portfolio. This action will also get you signed up to receive all further free reports as published automatically.
Thank You & Happy Hunting,
Disclosure: I am/we are long OCUL.